Stellanova Therapeutics hiring, advancing clinical pipeline after $15.5M raise

A Houston-based biotechnology firm plans to hire and develop a new discovery platform for its cancer therapeutics after a Series A raise. Stellanova Therapeutics is developing an antibody that targets fiber blast cells, which protect cancer cells against treatment and promote cancer cell growth. The company is initially targeting aggressive forms of cancer, like pancreatic cancer and triple-negative breast cancer, said Dr. Rosa Hwan g, co-founder of Stellanova and a member of the firm's scientific…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news

Related Links:

This article reviews the abnormal expression of miR-802 in a variety of tumors, expounds the mechanism by which miR-802 affects tumor progression by regulating different target genes, and elaborates the network of miR-802-related ceRNAs. We also summarized the limitations of miR-802 research and looked forward to the potential application of miR-802 in the diagnosis and prognosis of tumors.PMID:34558723 | DOI:10.1002/jcla.23989
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: The highly standardized analysis of a broad range of cancers identified a ranking order of tumors according to their relative prevalence of MUC5AC expression.PMID:34547930 | DOI:10.1177/15330338211043328
Source: Technology in Cancer Research and Treatment - Category: Cancer & Oncology Authors: Source Type: research
Conclusion[18F]FDG-PET/CT provided a high posterior probability of positive test, and a negative test was able to rule out distant metastases in women with clinically suspected recurrent breast cancer. One-fifth of patients examined for incidental findings detected on [18F]FDG-PET/CT were diagnosed with clinically relevant conditions. Further examinations of false-positive incidental findings in one of six women should be weighed against the high accuracy for diagnosing metastatic breast cancer.Trial registration Clinical.Trials.gov. NCT03358589. Registered 30 November 2017 —Retrospectively registered,http://www.ClinicalTrials.gov
Source: EJNMMI Research - Category: Radiology Source Type: research
ConclusionsOur cellular findings indicate that polyamine inhibition should be explored in patient population as a target for future chemotherapeutics in diabetic breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Approximately 10% of all colorectal cancer is estimated to be due to an inherited predisposition. Identification of a germline pathogenic variant can aid in treatment, screening, and surveillance and help stratify familial cancer risks based on gene-specific cancer associations. TheAPC gene contributes to a small percentage of hereditary colon cancer, with most pathogenicAPC variants causing familial adenomatous polyposis syndrome. However, one specific variant inAPC called p.I1307K, found in approximately 10% of Ashkenazi Jewish individuals, is associated with a moderate risk for colon cancer, but not polyposis. Heterozyg...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Planta Med DOI: 10.1055/a-1579-6454The lichen compound protolichesterinic acid (PA) has an anti-proliferative effect against several cancer cell lines of different origin. This effect cannot be explained by the known inhibitory activity of PA against 5- and 12-lipoxygenases. The aim was therefore to search for mechanisms for the anti-proliferative activity of PA. Two cancer cell lines of different origin, both sensitive to anti-proliferative effects of PA, were selected for this study, T-47D from breast cancer and AsPC-1 from pancreatic cancer. Morphological changes were assessed by transmission electron microscopy, HPLC c...
Source: Planta Medica - Category: Drugs & Pharmacology Authors: Tags: Original Papers Source Type: research
anlin Huang Germline BRCA1/2 mutations associated with HRD are clinical biomarkers for sensitivity to poly-ADP ribose polymerase inhibitors (PARPi) treatment in breast, ovarian, pancreatic, and prostate cancers. However, it remains unclear whether other mutations may also lead to HRD and PARPi sensitivity across a broader range of cancer types. Our goal was to determine the germline or somatic alterations associated with the HRD phenotype that might therefore confer PARPi sensitivity. Using germline and somatic genomic data from over 9000 tumors representing 32 cancer types, we examined associations between HRD scores ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Pancreatic cancer is the fourth most common cause of cancer deaths in the U.S. The overall 5-year survival rate is 8.5%. Glypican-1 (GPC1) is a cell surface heparan sulfate proteoglycan protein overexpressed in pancreatic cancer. Due to preferential expression, GPC1 represents a potential candidate for targeted therapy for pancreatic cancer and other GPC1-expressing cancers, such as prostate.Researchers at National Cancer Institute (NCI) developed novel Chimeric Antigen Receptors (CARs) specific for GPC1 that include short Immunoglobulin subclass 4 (IgG4) hinge sequences between the extracellular antigen recognition domain...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Tags: Therapeutics Collaboration Sought NCI Source Type: research
Programed Death-Ligand 1 (PD-L1, also known as B7-H1 or CD274) is a cell surface protein that binds to Programmed Cell Death Protein 1 (PD-1, also known as CD279). An imbalance in PD-1/PD-L1 activity contributes to cancer immune escape.   PD-1 is expressed on the surface of antigen-stimulated T cells. The interaction between PD-L1 and PD-1 negatively regulates T cell-mediated immune responses. It has been suggested that disrupting the PD-L1/PD-1 signaling pathway can be used to treat cancers. The aberrant expression of PD-L1 on mu ltiple tumor types supports this suggestion. As a result, PD-L1 represents a strong targ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Tags: Therapeutics Collaboration Sought NCI Source Type: research
Int J Clin Oncol. 2021 Sep 2. doi: 10.1007/s10147-021-02015-6. Online ahead of print.ABSTRACTPancreatic cancer is associated with both family and hereditary cancer syndromes. Multigene panel testing for pancreatic cancer detected the germline variants BRCA1/2, PALB2, ATM, TP53, MLH1, STK11/LKB1, APC, CDKN2A, and SPINK1/PRSS1 as high-risk genes. A latest genome-wide association study revealed the common, but low-risk germline variants in pancreatic cancer patients. Active pancreatic surveillance using magnetic resonance imaging and endoscopic ultrasound is recommended for high-risk individuals who have a family history of p...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | Health Management | Pancreas | Pancreatic Cancer